Zobrazeno 1 - 10
of 21
pro vyhledávání: '"329"'
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the
Publikováno v:
Blood. 110:1310-1310
Syk kinase is central to FcR and B-cell signaling in inflammatory cells. By inhibiting syk, and thereby IgG signaling, R788 (a small molecule prodrug for biologically active R406), inhibits the downstream activation of mast cells, macrophages and B-c
Autor:
Yanmin Zhao, Lizhen Liu, Yi Chen, Ying Lu, Jian Yu, Kang Yu, He Huang, Xiaoyu Lai, Jimin Shi, Huarui Fu, Fei Gao, Baodong Ye, Lieguang Chen, Jianping Lan, Xiaolu Song, Yi Luo
Publikováno v:
Blood. 138:1825-1825
Objective Hematopoietic stem cell transplantation (HSCT) is one of the most efficient treatments for hematologic malignancies. However, relapse remains the main cause of transplant failure. In myeloid neoplasia, the long-term survival for patients wh
Autor:
Jian-Ping Zhang, Rui-Juan Sun, Peihua Lu, Junfang Yang, Xian Zhang, Yan-Li Zhao, Jingjing Li, Min Xiong, Jia-Rui Zhou, De-Yan Liu, Yue Lu, Xing-Yu Cao, Zhi-Jie Wei
Publikováno v:
Blood. 136:40-41
Introduction Current available treatments are limited once patients with B-ALL relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While chimeric antigen receptor (CAR) T-cell therapy offers a chance of remission, long-t
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Rohtesh S. Mehta, Gregory P. Kaufman, Elisabet E. Manasanch, Neeraj Saini, Chitra Hosing, Uday R. Popat, Qaiser Bashir, Gabriela Rondon, Elizabeth J. Shpall, Partow Kebriaei, Krina K. Patel, May Daher, Ruby Delgado, Muzaffar H. Qazilbash, Stefan O. Ciurea, Yago Nieto, Issa F. Khouri, Samer A. Srour, Denái R. Milton, Robert Z. Orlowski, Richard E. Champlin, Hans C. Lee
Publikováno v:
Blood. 136:24-25
Introduction The role of upfront autologous stem cell transplantation (ASCT) for multiple myeloma (MM) has evolved over the last three decades, with significant improvements in preparative regimen, supportive care, induction, and maintenance therapy.
Autor:
Evandro D. Bezerra, Brenda M. Sandmaier, Linde M. Morsink, Megan Othus, H. Joachim Deeg, H. Gary Schoch, Brent L. Wood, Min Fang, Frederick R. Appelbaum, Roland B. Walter
Publikováno v:
Blood. 134:321-321
Background:Myeloablative allogeneic hematopoietic cell transplantation (HCT) is a common post-remission treatment strategy for medically fit adults with acute myeloid leukemia (AML) in morphologic remission. Several conditioning regimens have been ut
Autor:
Yuan-Shung Huang, Brian T. Fisher, Richard Aplenc, Karen R. Rabin, Kelly D. Getz, Jennifer J. Wilkes, Viviane C. Cahen, Yimei Li, Lena E. Winestone, Amanda M. DiNofia, M. Monica Gramatges, Alix E. Seif, Caitlin W Elgarten
Publikováno v:
Blood. 132:624-624
Administrative databases can be used to study outcomes including patients outside of clinical trials and have been used to identify relapse and HSCT in adult and adolescent/young adult leukemia populations. However, there are no published studies usi
Autor:
Erin Morris, John S. Holcenberg, F. Leonard Johnson, Stanton Goldman, Raymond J. Hutchinson, Jerry Z. Finklestein, Susan G. Kreissman, Elizabeth Harvey, Conrad Tou, Mitchell S. Cairo
Publikováno v:
Blood. 97:2998-3003
Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin
Autor:
Kimberly B. Dahlman, Megan L. Hames, Mahsa S. Talbott, Judy P. Tsai, Wade T. Iams, Nishitha Reddy, Kristy L. Richards
Publikováno v:
Blood. 124:4438-4438
Background: The use of lenalidomide is expanding to include patients with refractory or relapsed diffuse large B cell lymphoma (DLBCL). Lenalidomide is less toxic than thalidomide, but it leads to hypothyroidism in approximately 5-10% of patients tha